| Literature DB >> 25671501 |
Alexander V Aksenov1, Alexander N Smirnov, Igor V Magedov, Mary R Reisenauer, Nicolai A Aksenov, Inna V Aksenova, Alexander L Pendleton, Gina Nguyen, Robert K Johnston, Michael Rubin, Annelise De Carvalho, Robert Kiss, Véronique Mathieu, Florence Lefranc, Jaime Correa, David A Cavazos, Andrew J Brenner, Brad A Bryan, Snezna Rogelj, Alexander Kornienko, Liliya V Frolova.
Abstract
Many types of tumor, including glioma, melanoma, non-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multidrug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids that are active against apoptosis- and multidrug-resistant cancer cells as well as glioblastoma neurosphere stemlike cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25671501 PMCID： PMC4944210 DOI： 10.1021/jm501518y
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446